Dana-Farber News
@danafarbernews.bsky.social
Researchers from @danafarber.bsky.social are presenting 120+ studies at #ASH25. From non-chemo, time-limited lymphoma approaches (including Waldenström’s) to early sickle cell insights, Phase 3 MDS subgroup data, pediatric ALL, BPDCN, GVHD, and PROMISE screening.
Highlights: bit.ly/3XgqNLI
Highlights: bit.ly/3XgqNLI
November 25, 2025 at 3:00 PM
Researchers from @danafarber.bsky.social are presenting 120+ studies at #ASH25. From non-chemo, time-limited lymphoma approaches (including Waldenström’s) to early sickle cell insights, Phase 3 MDS subgroup data, pediatric ALL, BPDCN, GVHD, and PROMISE screening.
Highlights: bit.ly/3XgqNLI
Highlights: bit.ly/3XgqNLI
Heading to #CTOS25? Check out this list of @danafarber.bsky.social research presentations, panels, and posters that will be presented at the conference in Boca Raton, FL from Nov. 12-15.
November 11, 2025 at 3:30 PM
Heading to #CTOS25? Check out this list of @danafarber.bsky.social research presentations, panels, and posters that will be presented at the conference in Boca Raton, FL from Nov. 12-15.
In commentary published in Cancer Cell, @danafarber.bsky.social’s @judithagudo.bsky.social contends that integrating cancer cell phenotypic heterogeneity into spatial analyses is essential to reveal the mechanisms that generate TIME diversity and address resistance to immunotherapy. bit.ly/496Mc0Y.
November 7, 2025 at 3:30 PM
In commentary published in Cancer Cell, @danafarber.bsky.social’s @judithagudo.bsky.social contends that integrating cancer cell phenotypic heterogeneity into spatial analyses is essential to reveal the mechanisms that generate TIME diversity and address resistance to immunotherapy. bit.ly/496Mc0Y.
Now in Immunity: Research led by @vanallenlab.bsky.social finds immunotherapy resistance in #KidneyCancer is driven by myeloid cell signaling. This could help identify biomarkers to predict which patients are likely to respond to immunotherapy. @danafarber.bsky.social
➡️ bit.ly/47A0eWk
➡️ bit.ly/47A0eWk
October 31, 2025 at 3:40 PM
Now in Immunity: Research led by @vanallenlab.bsky.social finds immunotherapy resistance in #KidneyCancer is driven by myeloid cell signaling. This could help identify biomarkers to predict which patients are likely to respond to immunotherapy. @danafarber.bsky.social
➡️ bit.ly/47A0eWk
➡️ bit.ly/47A0eWk
Sara Tolaney, MD, of @danafarber.bsky.social publishes data from DESTINY Breast09 in @nejm.org showing T-DXd plus pertuzumab significantly prolonged progression-free survival compared to standard treatment in first-line therapy for metastatic HER2+ breast cancer.
➡️ bit.ly/3JxnaO5
➡️ bit.ly/3JxnaO5
October 29, 2025 at 11:15 PM
Sara Tolaney, MD, of @danafarber.bsky.social publishes data from DESTINY Breast09 in @nejm.org showing T-DXd plus pertuzumab significantly prolonged progression-free survival compared to standard treatment in first-line therapy for metastatic HER2+ breast cancer.
➡️ bit.ly/3JxnaO5
➡️ bit.ly/3JxnaO5
Congratulations to Dr. Chris Lathan of @danafarber.bsky.social, recipient of the Randolph W. “Bill” Bromery Legacy Award from @umassamherst.bsky.social for his deep commitment to social justice, diversity, equity, and inclusion.
➡️ bit.ly/4qvbFao
📷 Stephanie Berenson Photography
➡️ bit.ly/4qvbFao
📷 Stephanie Berenson Photography
October 28, 2025 at 2:48 PM
Congratulations to Dr. Chris Lathan of @danafarber.bsky.social, recipient of the Randolph W. “Bill” Bromery Legacy Award from @umassamherst.bsky.social for his deep commitment to social justice, diversity, equity, and inclusion.
➡️ bit.ly/4qvbFao
📷 Stephanie Berenson Photography
➡️ bit.ly/4qvbFao
📷 Stephanie Berenson Photography
In a study published in the Journal of Pediatric Psychology, @danafarber.bsky.social’s Dr. Eric Zhou highlights the Dana-Farber/Boston Children's Cancer and Blood Disorders Center’s new Sleep ALL Night program aiming to help children with leukemia sleep better during treatment. #ALL bit.ly/3Jxns7w
October 27, 2025 at 6:00 PM
In a study published in the Journal of Pediatric Psychology, @danafarber.bsky.social’s Dr. Eric Zhou highlights the Dana-Farber/Boston Children's Cancer and Blood Disorders Center’s new Sleep ALL Night program aiming to help children with leukemia sleep better during treatment. #ALL bit.ly/3Jxns7w
Congratulations to @danafarber.bsky.social’s Tomer Yaron-Barir, MD, PhD, who has been selected by @statnews.com as one of this year's #STATWunderkinds recognizing unheralded heroes of science and medicine.
Read more: bit.ly/3Js8S15
Read more: bit.ly/3Js8S15
October 24, 2025 at 5:30 PM
Congratulations to @danafarber.bsky.social’s Tomer Yaron-Barir, MD, PhD, who has been selected by @statnews.com as one of this year's #STATWunderkinds recognizing unheralded heroes of science and medicine.
Read more: bit.ly/3Js8S15
Read more: bit.ly/3Js8S15
Congratulations to Milen Negasi, a researcher in Dr. Xin Gu’s lab at @danafarber.bsky.social, who has been named to the Damon Runyon Scholars Program for Advancing Research and Knowledge (SPARK). The one-year cancer research internship is awarded to post-baccalaureate scholars.
October 23, 2025 at 6:30 PM
Congratulations to Milen Negasi, a researcher in Dr. Xin Gu’s lab at @danafarber.bsky.social, who has been named to the Damon Runyon Scholars Program for Advancing Research and Knowledge (SPARK). The one-year cancer research internship is awarded to post-baccalaureate scholars.
New research in @natgenet.nature.com from @danafarber.bsky.social’s @ckadoch.bsky.social and Jessica St. Laurent, MD, uncovers potential targeted therapy for endometrial cancer.
bit.ly/3Jq2Yxv
bit.ly/3Jq2Yxv
October 21, 2025 at 7:35 PM
New research in @natgenet.nature.com from @danafarber.bsky.social’s @ckadoch.bsky.social and Jessica St. Laurent, MD, uncovers potential targeted therapy for endometrial cancer.
bit.ly/3Jq2Yxv
bit.ly/3Jq2Yxv
Promising results for new combination therapy for ER+ HER2- #BreastCancer - Data presented by @danafarber.bsky.social’s Erica Mayer, MD, MPH, at #ESMO25 shows the combo may address resistance that often develops with current endocrine therapies. ➡️ bit.ly/46VQwyz
October 18, 2025 at 8:30 AM
Promising results for new combination therapy for ER+ HER2- #BreastCancer - Data presented by @danafarber.bsky.social’s Erica Mayer, MD, MPH, at #ESMO25 shows the combo may address resistance that often develops with current endocrine therapies. ➡️ bit.ly/46VQwyz
Lung cancer research at #ESMO25: Chemotherapy combo boosts overall survival in patients with EGFR-mutant non-small cell lung cancer. @danafarber.bsky.social's Dr. Pasi Jänne presents the complete data from phase 3 FLAURA2 study.
Press release ➡️bit.ly/47oV0hd
Press release ➡️bit.ly/47oV0hd
October 17, 2025 at 2:05 PM
Lung cancer research at #ESMO25: Chemotherapy combo boosts overall survival in patients with EGFR-mutant non-small cell lung cancer. @danafarber.bsky.social's Dr. Pasi Jänne presents the complete data from phase 3 FLAURA2 study.
Press release ➡️bit.ly/47oV0hd
Press release ➡️bit.ly/47oV0hd
As we observe Patient-Centered Care Awareness Month throughout October, we acknowledge our Nursing and Patient Care Services team whose clinical expertise, support and compassion shape every patient’s experience and set @danafarber.bsky.social apart.
Learn more about our approach at bit.ly/3Hec4wm.
Learn more about our approach at bit.ly/3Hec4wm.
October 16, 2025 at 2:00 PM
As we observe Patient-Centered Care Awareness Month throughout October, we acknowledge our Nursing and Patient Care Services team whose clinical expertise, support and compassion shape every patient’s experience and set @danafarber.bsky.social apart.
Learn more about our approach at bit.ly/3Hec4wm.
Learn more about our approach at bit.ly/3Hec4wm.
Important studies in breast, lung, and bladder cancers led or co-led by @danafarber.bsky.social researchers will be presented at #ESMO25 this week in Berlin. The ESMO Congress is one of the most important global oncology meetings and runs Oct 17-21.
Press release ➡️ bit.ly/4q1uodx
Press release ➡️ bit.ly/4q1uodx
October 14, 2025 at 12:00 PM
Important studies in breast, lung, and bladder cancers led or co-led by @danafarber.bsky.social researchers will be presented at #ESMO25 this week in Berlin. The ESMO Congress is one of the most important global oncology meetings and runs Oct 17-21.
Press release ➡️ bit.ly/4q1uodx
Press release ➡️ bit.ly/4q1uodx
New research published in @science.org led by @danafarber.bsky.social’s Doug Wassarman and @kranzuschlab.bsky.social reveals new protein chemistry named deazaguanylation that controls activation of immunity.
Read more: bit.ly/3WeKsLb
Read more: bit.ly/3WeKsLb
September 26, 2025 at 4:30 PM
New research published in @science.org led by @danafarber.bsky.social’s Doug Wassarman and @kranzuschlab.bsky.social reveals new protein chemistry named deazaguanylation that controls activation of immunity.
Read more: bit.ly/3WeKsLb
Read more: bit.ly/3WeKsLb
Through a first-of-its-kind program, @danafarber.bsky.social and Northeastern University are training the next generation of oncology nurses while setting a national standard for academic-clinical collaboration to meet urgent healthcare demands. #DanaFarber #NortheasternUniversity
➡️ bit.ly/48wd0Hp
➡️ bit.ly/48wd0Hp
September 25, 2025 at 1:15 PM
Through a first-of-its-kind program, @danafarber.bsky.social and Northeastern University are training the next generation of oncology nurses while setting a national standard for academic-clinical collaboration to meet urgent healthcare demands. #DanaFarber #NortheasternUniversity
➡️ bit.ly/48wd0Hp
➡️ bit.ly/48wd0Hp
“The New Face of Cancer” @danafarber.bsky.social’s Kimmie Ng, MD, MPH, joined Trisha Pasricha, MD, MPH, and Shuji Ogino, MD, PhD, at @bostonglobe.com's Future of Medicine Summit, discussing the alarming rise of cancer in adults younger than 55, moderated by @leungboston.bsky.social
September 24, 2025 at 7:00 PM
“The New Face of Cancer” @danafarber.bsky.social’s Kimmie Ng, MD, MPH, joined Trisha Pasricha, MD, MPH, and Shuji Ogino, MD, PhD, at @bostonglobe.com's Future of Medicine Summit, discussing the alarming rise of cancer in adults younger than 55, moderated by @leungboston.bsky.social
New research published in Nature led by @danafarber.bsky.social’s Edward Chouchani, PhD, identifies a protein that regulates the abundance of the metabolite cysteine, a major issue in cancer where numerous tumors rely on this metabolite to survive.
Read more: bit.ly/3IhAyp2
Read more: bit.ly/3IhAyp2
September 17, 2025 at 4:30 PM
New research published in Nature led by @danafarber.bsky.social’s Edward Chouchani, PhD, identifies a protein that regulates the abundance of the metabolite cysteine, a major issue in cancer where numerous tumors rely on this metabolite to survive.
Read more: bit.ly/3IhAyp2
Read more: bit.ly/3IhAyp2
On Apheresis Awareness Day, the Kraft Family Blood Donor Center honors donors, apheresis practitioners & patients for whom T-cells are removed, modified in the lab and infused back so they are stronger and ready to attack cancer head-on. #CARTCellTherapy #TCellCollection @danafarber.bsky.social
September 16, 2025 at 2:30 PM
On Apheresis Awareness Day, the Kraft Family Blood Donor Center honors donors, apheresis practitioners & patients for whom T-cells are removed, modified in the lab and infused back so they are stronger and ready to attack cancer head-on. #CARTCellTherapy #TCellCollection @danafarber.bsky.social
Congratulations to Pasi Jänne, MD, PhD, of @danafarber.bsky.social on receiving the Adi F. Gazdar IASLC Merit Award at #WCLC25 for his groundbreaking contributions to lung cancer research and patient care.
September 8, 2025 at 5:30 PM
Congratulations to Pasi Jänne, MD, PhD, of @danafarber.bsky.social on receiving the Adi F. Gazdar IASLC Merit Award at #WCLC25 for his groundbreaking contributions to lung cancer research and patient care.
A new study in @cp-molcell.bsky.social by @danafarber.bsky.social’s Mikołaj Słabicki, PhD, Benjamin Ebert, MD, PhD, and Eric Fischer, PhD, reports a systematic screen of 9,000 zinc fingers revealing 38 new CRBN-recruited degrons, expanding the ZF proteome map to guide drug design. bit.ly/41XoG1Q
August 26, 2025 at 2:30 PM
A new study in @cp-molcell.bsky.social by @danafarber.bsky.social’s Mikołaj Słabicki, PhD, Benjamin Ebert, MD, PhD, and Eric Fischer, PhD, reports a systematic screen of 9,000 zinc fingers revealing 38 new CRBN-recruited degrons, expanding the ZF proteome map to guide drug design. bit.ly/41XoG1Q
New research from @danafarber.bsky.sociall’s Rinath Jeselsohn, MD, and colleagues in Nature Genetics sheds light on why tamoxifen may lead to higher risk of uterine cancer.
➡️ bit.ly/45Aq3pI
➡️ bit.ly/45Aq3pI
August 25, 2025 at 7:00 PM
New research from @danafarber.bsky.sociall’s Rinath Jeselsohn, MD, and colleagues in Nature Genetics sheds light on why tamoxifen may lead to higher risk of uterine cancer.
➡️ bit.ly/45Aq3pI
➡️ bit.ly/45Aq3pI
Research published in @cp-molcell.bsky.social co-led by Renee Chang of @danafarber.bsky.social’s @kranzuschlab.bsky.social reveals how Acb4 proteins distinguish between immune & homeostatic signals and the evolution of sponge proteins to recognize immune signals in host environments. bit.ly/4fOeI8U
August 25, 2025 at 2:30 PM
Research published in @cp-molcell.bsky.social co-led by Renee Chang of @danafarber.bsky.social’s @kranzuschlab.bsky.social reveals how Acb4 proteins distinguish between immune & homeostatic signals and the evolution of sponge proteins to recognize immune signals in host environments. bit.ly/4fOeI8U
Some prostate cancers evade therapy by transforming into aggressive neuroendocrine prostate cancer. New research highlights PROX1 as a key driver of this transformation and tumor growth, offering a potential treatment target.
➡️ bit.ly/4lEFHoD
➡️ bit.ly/4lEFHoD
August 22, 2025 at 2:30 PM
Some prostate cancers evade therapy by transforming into aggressive neuroendocrine prostate cancer. New research highlights PROX1 as a key driver of this transformation and tumor growth, offering a potential treatment target.
➡️ bit.ly/4lEFHoD
➡️ bit.ly/4lEFHoD
New research in @jamaoncology.bsky.social from @danafarber.bsky.social’s Jennifer Ligibel, MD, shows remote weight loss intervention helped #breastcancer survivors reduce weight. Investigators will evaluate if weight loss can help prevent recurrence. Critical support by Susan G. Komen bit.ly/4mBlHEw
August 21, 2025 at 3:30 PM
New research in @jamaoncology.bsky.social from @danafarber.bsky.social’s Jennifer Ligibel, MD, shows remote weight loss intervention helped #breastcancer survivors reduce weight. Investigators will evaluate if weight loss can help prevent recurrence. Critical support by Susan G. Komen bit.ly/4mBlHEw